

- Name: Riluzole
- Effect:

Riluzole was approved in the United States for the treatment of ALS by the FDA in 1995. A Cochrane Library review states a 9% gain in the probability of surviving one year.
- Usage:

Amyotrophic lateral sclerosis
- Subject affect:
  - Amyotrophic lateral sclerosis

Riluzole was approved in the United States for the treatment of ALS by the FDA in 1995. A Cochrane Library review states a 9% gain in the probability of surviving one year.
- Side effect:
  - Very common (>10% frequency): nausea; weakness; decreased lung function
  - Common (1–10% frequency):[5] headache; dizziness; drowsiness; vomiting; abdominal pain; increased aminotransferases
  - Uncommon (0.1-1% frequency):[5] pancreatitis; interstitial lung disease
  - Rare (<0.1% frequency):[5] neutropenia; allergic reaction (including angiooedema, anaphylactoid reaction)
- Precautions:

Contraindications for riluzole include: known prior hypersensitivity to riluzole or any of the excipients inside the preparations, liver disease, pregnancy or lactation.